Search research articles
Contact Us
Filters
Showing results (131-140 of 162) with videos related to
Page
of 17
Sort By:
BMJ Open
|
October 22, 2024
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
Daniel Vincent O'Hara, Abhinav Bassi, Arlen Wilcox, et al.
Kidney International Reports
|
September 12, 2022
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility
Glen James, Juan Jose Garcia Sanchez, Juan Jesus Carrero, et al.
JMIR Research Protocols
|
April 15, 2020
EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study
Celine Foote, Carinna Hockham, Louisa Sukkar, et al.
Journal of the American Heart Association
|
June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
BMJ (Clinical Research Ed.)
|
November 17, 2022
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
Meg J Jardine, Sradha S Kotwal, Abhinav Bassi, et al.
Trials
|
August 20, 2015
Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis
Allison Tong, Braden Manns, Brenda Hemmelgarn, et al.
Journal of Clinical & Translational Endocrinology
|
December 9, 2020
Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data
Hongmei Zhang, Kris Rogers, Louisa Sukkar, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 162) with videos related to
Sort By:
Page
of 17
BMJ Open
|
October 22, 2024
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
Daniel Vincent O'Hara, Abhinav Bassi, Arlen Wilcox, et al.
Kidney International Reports
|
September 12, 2022
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility
Glen James, Juan Jose Garcia Sanchez, Juan Jesus Carrero, et al.
JMIR Research Protocols
|
April 15, 2020
EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study
Celine Foote, Carinna Hockham, Louisa Sukkar, et al.
Journal of the American Heart Association
|
June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
BMJ (Clinical Research Ed.)
|
November 17, 2022
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
Meg J Jardine, Sradha S Kotwal, Abhinav Bassi, et al.
Trials
|
August 20, 2015
Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis
Allison Tong, Braden Manns, Brenda Hemmelgarn, et al.
Journal of Clinical & Translational Endocrinology
|
December 9, 2020
Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data
Hongmei Zhang, Kris Rogers, Louisa Sukkar, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Page
of 17